VON RICKENBACH JOSEF H 4
4 · Rein Therapeutics, Inc. · Filed May 28, 2026
Research Summary
AI-generated summary of this filing
Rein Therapeutics (RNTX) Director Josef von Rickenbach Buys Stock
What Happened
Josef H. von Rickenbach, a director of Rein Therapeutics (RNTX), made multiple open‑market purchases totaling 47,060 shares between May 21 and May 27, 2026. Reported daily weighted‑average prices and amounts: 3,420 shares @ $1.04 ($3,564) on 5/21; 15,950 shares @ $1.05 ($16,708) on 5/22; 23,190 shares @ $1.06 ($24,470) on 5/26; and 4,500 shares @ $1.07 ($4,819) on 5/27. Total reported cost was approximately $49,561. These were purchases (insider buys), which investors often view as a more informative signal than routine sales.
Key Details
- Transaction dates/prices (weighted averages reported):
- 2026-05-21: 3,420 sh @ $1.04 = $3,564
- 2026-05-22: 15,950 sh @ $1.05 = $16,708
- 2026-05-26: 23,190 sh @ $1.06 = $24,470
- 2026-05-27: 4,500 sh @ $1.07 = $4,819
- Total acquired: 47,060 shares for ~$49,561.
- Shares owned after transaction: not specified in the summary provided (see full Form 4 for total holdings).
- Footnote: purchases were executed in multiple trades at prices within daily ranges (e.g., $1.03–$1.08 across days). The filing notes the reporting person will provide a full breakdown of the number of shares bought at each separate price on request.
- Filing: Form 4 was filed 2026‑05‑28 and reports trades from 2026‑05‑21 through 2026‑05‑27; the filing date is immediately after the last reported trade (5/27).
Context
- These are open‑market purchases (transaction code P) by a company director. Purchases by insiders can signal confidence but are not proof of future performance.
- No options exercises, gifts, or tax‑withholding events are reported here.
- For complete context (total insider holdings, exact per‑price execution details, or 10%‑owner status), consult the full SEC Form 4 filing (Accession 0001193125-26-245832).
Insider Transaction Report
- Purchase
Common stock , $0.001 par value
[F1]2026-05-21$1.04/sh+3,420$3,564→ 18,874 total - Purchase
Common stock , $0.001 par value
[F1]2026-05-22$1.05/sh+15,950$16,708→ 34,824 total - Purchase
Common stock , $0.001 par value
[F1]2026-05-26$1.06/sh+23,190$24,470→ 58,014 total - Purchase
Common stock , $0.001 par value
[F1]2026-05-27$1.07/sh+4,500$4,819→ 62,514 total
Footnotes (1)
- [F1]The reported shares were purchased in the open market in multiple transactions at prices ranging from $1.05 and $1.035 on May 21, 2026, $1.07 and $1.01 on May 22, 2026, $1.07 and $1.03 on May 26, 2026 and $1.08 and $1.03 on May 27, 2026. The prices reported in Column 4 are a weighted average price for purchase on the respective day. The reporting person undertakes to provide to Rein Therapeutics, Inc., any stockholder of Rein Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1).